TUMEURS COLORECTALES
- Cotte E, et al. Rectal cancer – French intergroup clinical practice guidelines for diagnosis, treatment, and follow-up (TNCD, SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFP, RENAPE, SNFCP, AFEF, SFR, and GRECCAR). Dig Liver Dis. 2025 Mar;57(3):669-679. doi: 10.1016/j.dld.2024.12.004. Epub 2024 Dec 17. PMID: 39694751
- Taieb J, et al. Combined Analyses of Circulating Tumor DNA and Immunoscore in Patients With Stage III Colon Cancer: A Post Hoc Analysis of the PRODIGE-GERCOR IDEA-France/HORG-IDEA-Greece Trials. J Clin Oncol. 2025 May;43(13):1564-1577. doi: 10.1200/JCO.24.00648. Epub 2025 Feb 4. PMID: 39903903
- Depotte L, et al. Interplay between sarcopenia, GDF-15, and the efficacy of nivolumab plus ipilimumab in patients with mismatch repair deficient metastatic colorectal cancer: final survival analysis of the phase II GERCOR NIPICOL study. J Immunother Cancer. 2025 May 19;13(5):e011220. doi: 10.1136/jitc-2024-011220. PMID: 40389373
- Parent P, et al. Muscle Loss During First-Line Chemotherapy Impairs Survival in Advanced Pancreatic Cancer Despite Adapted Physical Activity. J Cachexia Sarcopenia Muscle. 2025 Feb;16(1):e13595. doi: 10.1002/jcsm.13595. Epub 2025 Jan 17. PMID: 39825571
- Lefevre JH, et al. Neoadjuvant pembrolizumab with a watch‑and‑wait strategy for localized MSI/dMMR colon cancer: Study protocol for a randomized GERCOR 109 – PRODIGE 84 phase II trial (PREMICES). Dig Liver Dis. 2026 Jan;58(1):51-55. doi: 10.1016/j.dld.2025.11.003. Epub 2025 Nov 22. PMID: 41276451
- Taieb J, et al. Promoting large multinational academic clinical trials for gastrointestinal cancers in Europe: the ENGIC (European Network for GI Cancers) initiative. ESMO Open. 2025 May;10(5):105055. doi: 10.1016/j.esmoop.2025.105055. Epub 2025 May 6. PMID: 40334313
- Gallois C, et al. Prognostic Models From Transcriptomic Signatures of the Tumor Microenvironment and Cell Cycle in Stage III Colon Cancer From PETACC-8 and IDEA-France Trials. J Clin Oncol. 2025 May 20;43(15):1765-1776. doi: 10.1200/JCO.23.02262. Epub 2025 Jan 31. PMID: 39889251
- Vienot A, et al. Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A Post Hoc Biomarker Analysis of the TEXCAN and CORRECT Trials. Cancer Res Commun. 2025 Feb 1;5(2):287-294. doi: 10.1158/2767-9764.CRC-24-0246. PMID: 39807836
- Pilati C, et al. ERBB2 Comprehensive Profiling and Prognostication in Stage III Colon Cancer: Findings From PETACC8 and IDEA-France Cohorts. Gastroenterology. 2025 Apr;168(4):714-724.e4. doi: 10.1053/j.gastro.2024.10.046. Epub 2024 Nov 28. PMID: 39612956
- Delaye M, et al. Durvalumab plus tremelimumab after platinum failure in biliary tract cancer: IMMUNOBIL PRODIGE 57. Annals of Oncology (2025) 36 (suppl_2): S233-S244. 10.1016/annonc/annonc1902. Mini Oral session: 80MO. 2025 ESMO Congress
- Cohen R, et al. Efficacy and safety of two schemes of nivolumab and ipilimumab in MSI/dMMR metastatic CRC: PRODIGE-74 GERCOR NIPISAFE phase II trial. ESMO 2025, Annals of Oncology (2025) 36 (suppl_2): S506-S599. 10.1016/annonc/annonc1915. Poster 812P.
- Cohen R, et al. Nivolumab and ipilimumab in anti-PD1-resistant MSI/dMMR metastatic CRC: Interim analysis of GERCOR NIPIRESCUE phase II trial. ESMO 2025, Ann Oncol. 2025;36(suppl_2):S506-S599. DOI:10.1016/annonc/annonc1915. ePoster 879eP
- Depotte L, et al. Nivolumab plus ipilimumab in MSI/dMMR metastatic CRC: Final survival analysis and prognostic evaluation of GDF-15 in GERCOR NIPICOL phase II study. ESMO 2025, Abstract 544P. Ann Oncol. 2025;36(suppl_2):S506-S599. DOI:10.1016/annonc/annonc1915
- Blanchet-Deverly S, et al. Biological and therapeutic impact of tumor mutational burden in MSI/dMMR metastatic CRC treated with ICIs. J Clin Oncol. 2025;43(4_suppl):272-272. Abstract 272, Poster Bd: L6. NIPICOL study. 2025 ASCO GI
- Kempf E, et al. Acupuncture in oxaliplatin-induced peripheral neuropathy (NPIO) in patients with digestive tumors: Results of Cohort 2 of ACUPOX GERCOR G-114 Study. 38th ICMART 2025, Antibes, Abstract + Oral presentation
- Kempf E, et al. Intérêt de l’acupuncture dans la neuropathie périphérique induite par l’oxaliplatine chez patients exposés à l’oxaliplatine: Analyse intermédiaire cohorte 2 (C2). JFHOD 2025, Abstract. Poster P424.
- Basile D, Broudin C, Emile JF, et al. Tumor budding is an independent prognostic factor in stage III colon cancer patients: a post-hoc analysis of the IDEA-France phase III trial (PRODIGE-GERCOR). Ann Oncol. 2022;33(6):628-637.
- Cohen R, Raeisi M, Chibaudel B, et al. Efficacy of immune checkpoint inhibitors for metastatic CRC with MSI in second or later line using synthetic control arms: NIPICOL. Eur J Cancer. 2024;199:113537.
- Gandini A, Gallois C, Blons H, et al. Genetic and transcriptomic analyses of Early-Onset Colon Cancer (EOCC): A post-hoc analysis of 2973 patients. Ann Oncol. 2024;35(Suppl 2):S428-S481. ESMO 2024, Abstract, Poster session 16.
- Taieb J, Souglakos I, Boukovinas I, et al. Combined analyses of ctDNA and Immunoscore in stage III colon cancer patients: post hoc analysis of IDEA-France and -Greece trials. Ann Oncol. 2024;35(Suppl 1):S1-S74. ESMO 2024, Abstract 317MO, Mini Oral session: GI.
- Borg C, Dourthe L, Andre T, et al. Angiopietin-2 (Ang-2) as a potential biomarker for guiding bevacizumab or anti-EGFR in RAS/BRAF wt unresectable mCRC: exploratory analysis of STRATEGIC-1. Ann Oncol. 2024;35(Suppl 1):S1-S74. ESMO GI 2024, Abstract; Poster 116P.
- Depotte L, Nay P, Borg C, et al. Nivolumab plus ipilimumab in MSI/dMMR metastatic CRC: Final survival analysis and prognostic evaluation of GDF-15 in GERCOR NIPICOL phase II study. Ann Oncol. 2024;35(Suppl 2):S428-S481. ESMO 2024, Abstract 544P; Poster.
- Bachet JB, Bouché O, Trouilloud I, et al. G-CSF secondary prophylaxis with FTD/TPI in mCRC: LONGBOARD. Ann Oncol. 2024;ESMO:6818; Poster 532P.
- Ratovomanana T, Nicolle R, Cohen R, et al. Prediction of response to immune checkpoint blockade in metastatic CRC with microsatellite instability: NIPICOL. Ann Oncol. 2023;34:703-713.
- Gallois C, Sroussi M, André T, et al. Predictive models of recurrence from transcriptomic signatures in stage III colon cancer (PETACC-8 and IDEA France trials). J Clin Oncol. 2023;41(Suppl 16; abstr 3523). ASCO Annual Meeting, Abstract 3523; Poster 223.
- Basile D, Broudin C, Emile JF, et al. Tumor budding is an independent prognostic factor in stage III colon cancer patients: post-hoc analysis of the IDEA-France phase III trial (PRODIGE-GERCOR). Ann Oncol. 2022;33:628-637.
- Rousseau B, Boukerma AK, Henriques J, et al. Impact of regorafenib and metabolite concentrations on OS in chemorefractory metastatic CRC: GERCOR TEXCAN study. Eur J Cancer. 2022;168:99-107.
- Jary M, Liu WW, Yan D, et al. Immune microenvironment in mismatch-repair-proficient oligometastatic CRC exposed to chemotherapy: MIROX GERCOR cohort study. Mol Oncol. 2022;16:2260-2273.
- Claire Gallois, Qian Shi, Meyers JP, et al. Prognostic impact of early treatment and oxaliplatin discontinuation in stage III colon cancer: ACCENT/IDEA pooled analysis. J Clin Oncol 41, 803-815 (2023). ASCO Gastrointestinal Cancers Symposium 2022, Abstract 11.
- Cohen R, Meurisse A, Pudlarz T, et al. One-year duration of nivolumab plus ipilimumab in MSI/dMMR metastatic CRC: long-term follow-up of GERCOR NIPICOL phase II study. ASCO Gastrointestinal Cancers Symposium 2022, Abstract 13 & Poster C.
- Chibaudel B, Dourthe LM, Andre T, et al. STRATEGIC-1: Multi-line therapy trial in unresectable KRAS/NRAS/BRAF wild-type metastatic CRC. J Clin Oncol 40, 2022 (suppl 16; abstr 3504). ASCO Annual Meeting, Oral Abstract Session.
- Chibaudel B, Dourthe LM, Andre T, et al. Multi-line therapy trial in unresectable RAS/BRAF wild-type metastatic CRC: phase III STRATEGIC-1 GERCOR-PRODIGE study. ESMO 2022, Abstract 5313.
- Carola E, Chibaudel B, Boulahssass R, et al. Impact of age on treatment strategies in RAS/BRAF wild-type metastatic CRC: prespecified subgroup of STRATEGIC-1. ESMO 2022, Abstract 5523 & Poster 309P.
- Taieb J, Taly V, Henriques J, et al. Prognostic value and relation with adjuvant treatment duration of ctDNA in stage III colon cancer: post hoc analysis of PRODIGE-GERCOR IDEA-France trial. Clin Cancer Res. 2021;27:5638-5646.
- Fontana E, Meyers J, Sobrero A, et al. Early-onset colorectal adenocarcinoma in the IDEA database: treatment adherence, toxicities, and outcomes with 3 and 6 months of adjuvant therapy. J Clin Oncol. 2021;39:4009-4019.
- Fontana E, Meyers J, Sobrero A, et al. Early-Onset Colorectal Adenocarcinoma in the IDEA Database: Treatment Adherence, Toxicities, and Outcomes With 3 and 6 Months of Adjuvant Fluoropyrimidine and Oxaliplatin. J Clin Oncol 39, 4009-4019 (2021). ASCO Annual Meeting, Abstract 3517.
- Basile D, Broudin C, Emile JF, et al. Tumor budding as an important prognostic factor in stage III colon cancer patients treated with oxaliplatin-based chemotherapy. Ann Oncol 32 (suppl_5): S530-S582. Mini oral session 388MO. ESMO Immuno-Oncology Congress 2021.
- Pastor B, André T, Henriques J, et al. Monitoring circulating cfDNA as biomarker of response to regorafenib in metastatic CRC: TEXCAN study. Mol Oncol. 2021;15:2401-2411.
- Ouali K, Turpin A, Neuzillet C, et al. Impact of IDEA results on clinical practice in France. Clin Colorectal Cancer. 2021;20:79-83.
- Basile D, Gallois C, Puglisi F, et al. Practices and expectations on the use of circulating tumor DNA in colorectal cancer patients: a bi‑national AGEO/AIOM/GERCOR/FFCD/FRENCH survey. Clin Res Hepatol Gastroenterol. 2021;45(3):101681. doi:10.1016/j.clinre.2021.101681.
- Pagès F, André T, Taieb J, et al. Prognostic and predictive value of the Immunoscore in stage III colon cancer. Ann Oncol. 2020;31:921-929.
- André T, Vernerey D, Im SA, et al. Bevacizumab as adjuvant treatment of colon cancer: updated AVANT results. Ann Oncol. 2020;31:246-256.
- Chibaudel B, André T, Tournigand C, et al. Prognostic value of tumor location and KRAS: OPTIMOX3 DREAM analysis. Clin Colorectal Cancer. 2020;19:200-208.
- Sobrero AF, Puccini A, Shi Q, et al. A new prognostic tool for shared decision making in stage III colon cancer. Eur J Cancer. 2020;138:182-188.
- Delattre JF, Cohen R, Henriques J, et al. Prognostic value of tumor deposits in stage III colon cancer. J Clin Oncol. 2020;38:1702-1710.
- Cohen R, Bennouna J, Meurisse A, et al. RECIST and iRECIST evaluation of nivolumab plus ipilimumab: NIPICOL study. J Immunother Cancer. 2020;8:e001499.
- Chibaudel B, Henriques J, Rakez M, et al. Bevacizumab plus oxaliplatin and survival in stage II colon cancer: AVANT trial. JAMA Netw Open. 2020;3:e2020425.
- Pagès F, Taieb J, Laurent-Puig P, et al. The consensus Immunoscore in phase III clinical trials. Oncoimmunology. 2020;9:1812221.
- Makhloufi S, Turpin A, El Amrani M, et al. Fong’s score in metastatic CRC: MIROX trial analysis. Ann Surg Oncol. 2020;27:877-885.
- Galon J, Hermitte F, Mlecnik B, et al. Immunoscore predicting recurrence and DFS in T4N0 stage II colon cancer. J Clin Oncol. 2020;38(suppl; abstr 4105). Abstract + oral (ASCO Virtual Scientific Program)
- Pagès F, André T, Taieb J, et al. Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with mFOLFOX6 in IDEA France cohort. J Clin Oncol. 2020;38(suppl 4; abstr 10). Abstract + oral (GI Cancers Symposium)
- Sobrero AF, André T, Meyerhardt JA, et al. OS and DFS of 3 vs 6 months adjuvant therapy: IDEA collaboration. J Clin Oncol. 2020;38 (abstr 4004).
- Pudlarz T, Montravers F, Garcia-Larnicol ML, et al. 18FDG-PET/CT in MSI metastatic CRC treated with ICIs. Ann Oncol. 2020;31(abstr 46P).
- Cohen R, Bennouna J, Henriques J, et al. RECIST and iRECIST criteria in MSI/dMMR mCRC: NIPICOL study. J Clin Oncol. 2020;38. 2020 ASCO GI: Abstract 101, Poster Bd: E9.
- Margalit O, Boursi B, Rakez M, et al. Benefit of oxaliplatin in stage III colon cancer according to IDEA risk groups: analysis of MOSAIC and C‑07 trials. J Clin Oncol. 2020;38(4_suppl):118. ASCO 2020 Annual Meeting: Abstract 118, Poster Bd F4.
- Di Fiore F, Bouché O, Lepage C, et al. Management of digestive cancers during the COVID-19 epidemic: French intergroup recommendations. Dig Liver Dis. 2020;52(6):597-603. doi:10.1016/j.dld.2020.03.031.
- Hilmi M, Pellat A, Benoit O, et al. Nutrition and physical activity education in gastrointestinal oncology: a national survey. BMJ Support Palliat Care. 2020;10(3):324-330. doi:10.1136/bmjspcare-2020-002342.
- Lièvre A, Turpin A, Ray-Coquard I, et al. Risk factors for COVID-19 severity and mortality among patients with solid tumors: French nationwide cohort (GCO-002 CACOVID-19). 2020.
- Tougeron D, Michel P, Lièvre A, et al. Management of digestive cancers during the COVID-19 second wave: A French intergroup point of view (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFR). Dig Liver Dis. 2021 Mar;53(3):306-308. doi: 10.1016/j.dld.2020.11.029.
